Platelet Factor 4
Platelet factor 4 (CXCL4)
Written by Aaron CuhaReviewed Sep 2026
Also known as: PF4, CXCL4, Platelet-derived chemokine
A platelet chemokine that three independent laboratories reported in 2023 restores cognition in aged mice. It is higher in young human plasma than old, and has never been given to a person.
Overview
In August 2023 three independent groups published in Nature Communications, Nature and Nature Aging within a month of each other, all converging on the same molecule. Platelet factor 4, also called CXCL4, is a chemokine released by platelets. Systemic exposure of aged mice to a platelet-containing fraction of young mouse plasma reduced hippocampal neuroinflammation and improved hippocampal-dependent cognition, and administering PF4 on its own reproduced the effect. One group framed it as an exercise factor, one as a young-blood factor, and one as downstream of klotho, the longevity protein this site covers separately. Mechanistically the Nature paper implicated the chemokine receptor CXCR3 as mediating part of the benefit.
Simultaneous convergence by three laboratories is unusual and is the strongest feature of this literature. What it does not do is make any of it human. All three papers are mouse studies.
The human component is a measurement: circulating PF4 was reported as elevated in blood plasma preparations of young mice and young humans relative to older individuals. No human has received PF4 as a treatment, and no trial is registered.
PF4 does have a substantial human clinical literature, and it is worth knowing because it is a warning rather than a support. PF4 is the antigen in heparin-induced thrombocytopenia: antibodies against complexes of PF4 and heparin activate platelets and cause thrombosis, sometimes severe. Anything that raises PF4 in a person is entering territory where the protein's best-documented human role is immune-mediated clotting.
Mechanism of action
In mice, systemic PF4 reduces age-related hippocampal neuroinflammation at transcriptional and cellular levels, produces molecular changes associated with synaptic plasticity, and improves cognition, with the chemokine receptor CXCR3 mediating part of the effect and with restoration of the ageing peripheral immune system implicated. One of the 2023 papers places PF4 downstream of klotho. In humans, the established biology is haemostatic and immunological: PF4 is released from platelet alpha granules, binds heparin and related glycosaminoglycans, and PF4-heparin complexes are the antigenic target in heparin-induced thrombocytopenia. No human cognitive mechanism has been demonstrated.
Human evidence
None as an intervention. No human has received platelet factor 4. The human data are a measurement, that circulating PF4 is higher in young than older people, and a large clinical literature about PF4 as the antigen in heparin-induced thrombocytopenia, which is about clotting rather than cognition.
- The 2023 Nature paper reports that circulating PF4 levels were elevated in blood plasma preparations of young humans relative to older individuals, alongside the same finding in mice. That is an observational measurement in human samples, not an intervention.
- No registered trial of PF4 administration for cognition, ageing or any other indication could be located.
- The established human clinical role of PF4 is as the antigen in heparin-induced thrombocytopenia, in which antibodies to PF4-heparin complexes activate platelets and cause thrombosis. This is a well-characterised human condition and it is the main reason systemic PF4 dosing in people is not a straightforward proposition.
What this does not tell you: Three convergent mouse papers do not make a human finding. Nothing is known about whether PF4 given to a person improves cognition, and the one thing well established about PF4 in humans is a pathological immune reaction involving it. Any human programme would need to address that directly, and none has been registered.
Reading the research record
The simultaneous publication of three independent PF4 papers in August 2023, in Nature, Nature Communications and Nature Aging, is the most convincing thing about this molecule. Independent convergence is the strongest signal a preclinical field produces, and it is worth more than any single paper however prominent. It is also a reason to expect the human question to be asked, and three years later it has not been.
The likely reason sits in the human literature rather than the mouse literature. PF4's documented role in people is as the antigen in heparin-induced thrombocytopenia, a serious immune-mediated clotting disorder. Giving a healthy older adult systemic PF4 to improve memory means raising a protein whose human claim to fame is prothrombotic immune pathology, and no sponsor has registered a trial that takes that on.
The klotho link is worth following for readers of this site, because klotho has its own entry and its own human programme. One of the 2023 papers positions platelet factors as downstream of klotho, which would make PF4 part of the mechanism of a protein already in clinical development rather than a standalone target.
The evidence, charted
Fig. 1 · evidence composition
0of 4 citations (0%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2017 and 2023.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2023
Platelet factors attenuate inflammation and rescue cognition in ageing
Mouse. Systemic exposure of aged male mice to a platelet-containing fraction of young mouse plasma decreased hippocampal neuroinflammation at transcriptional and cellular levels and improved hippocampal-dependent cognition. Circulating PF4 was elevated in plasma preparations of young mice and young humans relative to older individuals. Systemic PF4 alone attenuated age-related hippocampal neuroinflammation and improved cognition in aged mice, with CXCR3 identified as partly mediating the effect. NIH funded.
Nature - Animal2023
Platelet-derived exerkine CXCL4/platelet factor 4 rejuvenates hippocampal neurogenesis and restores cognitive function in aged mice
Mouse. PF4 characterised as an exercise-released factor that rejuvenates hippocampal neurogenesis and restores cognitive function in aged mice. One of three independent papers published within a month reaching a convergent conclusion. NIH funded with non-US government support.
Nature Communications - Animal2023
Platelet factors are induced by longevity factor klotho and enhance cognition in young and aging mice
Mouse. Platelet factors including PF4 are induced by klotho and enhance cognition in both young and ageing mice, placing PF4 downstream of a longevity protein this site covers separately. NIH funded.
Nature Aging - Review2017
Heparin-induced thrombocytopenia
Human clinical review of heparin-induced thrombocytopenia, the condition in which antibodies to complexes of platelet factor 4 and heparin activate platelets and cause thrombosis. This is the context in which PF4 is measured in people and the reason its human profile is a caution rather than a support. It is not an ageing study.
Blood
Frequently asked questions
Has PF4 been given to a human?
No. There is no administration study and no registered trial of platelet factor 4 for cognition, ageing or anything else. The three 2023 papers that generated the interest are all mouse studies.
Why did three papers appear at once?
Three independent laboratories converged on the same molecule and published in Nature, Nature Communications and Nature Aging within a month in August 2023, framing it respectively as a young-blood factor, an exercise factor and a klotho-induced factor. Independent convergence is the strongest kind of preclinical signal, and it is still preclinical.
Is raising PF4 risky?
It has not been tested in a person, so there is no direct answer. What is established in humans is that antibodies against complexes of PF4 and heparin cause heparin-induced thrombocytopenia, a serious clotting disorder. That is the human role of this protein with the largest clinical literature behind it, and it is the obvious question any human programme would have to answer first.
How does this relate to klotho?
One of the 2023 papers, in Nature Aging, reported that platelet factors including PF4 are induced by klotho and enhance cognition in young and ageing mice. If that holds, PF4 would be part of the downstream mechanism of klotho rather than an independent target. Klotho has its own entry on this site with its own clinical programme.